Integration of Hypertension Management in HIV Care in Uganda (PULESAUganda)
HIV/AIDS, Hypertension
About this trial
This is an interventional health services research trial for HIV/AIDS
Eligibility Criteria
Inclusion Criteria: 1) All patients over 18 years of age receiving care at participating HIV clinics will contribute data for the effectiveness outcomes Exclusion Criteria: 1) Patients who are not diagnosed with HIV receiving care at participating HIV clinics and are under the age of 18.
Sites / Locations
- ButabikaRecruiting
- KawalaRecruiting
- KisenyiRecruiting
- KitebiRecruiting
- KomambogaRecruiting
- Mengo HospitalRecruiting
- NaguruRecruiting
- NsambyaRecruiting
- BweyogerereRecruiting
- Entebbe RRHRecruiting
- KakiriRecruiting
- KawandaRecruiting
- Nakawuka HCIIIRecruiting
- Nsangi HCIIIRecruiting
- Nurture AfricaRecruiting
- SaidinaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
No Intervention
8 HIV clinics randomized to HTN BASIC
8 HIV clinics randomized to HTN PLUS
Control Period for all 16 clinics
The HTN-BASIC intervention will consist of providing consistent access to diagnostic equipment and evidence-based antihypertensive drugs at no cost to the hypertensive patients. Access to a consistent supply of three anti-hypertensive drugs (amlodipine 5, 10mg; valsartan 80, 160mg; and hydrochlorothiazide 12.5, 25mg) will be supplied to each clinic in the trial.
In addition to receiving all the components of HTN-BASIC, HTN-PLUS sites will receive an enhanced, more human-resource intensive package of interventions that have been developed in consultation with key stakeholders during our human-centered design phase. The intervention components will include four broad categories- (1) hypertension training, (2) differentiated service delivery and (3) remote patient monitoring for hypertension and (4) Performance Improvement Program. Uptake of all components will be assessed on a monthly basis during the intervention period. These interventions will by nature cost more, and so cost data will be rigorously collected as well.
Outcome data will be collected during the control period prior to intervention roll-out in all 16 clinics.